Frequency of TERT promoter mutations in human cancers by Vinagre, João et al.
ARTICLE
Received 19 Apr 2013 | Accepted 25 Jun 2013 | Published 26 Jul 2013
Frequency of TERT promoter mutations in human
cancers
Joa˜o Vinagre1,2,*, Ana Almeida1,2,*, Helena Po´pulo1,*, Rui Batista1, Joana Lyra1,3, Vasco Pinto1,3, Ricardo Coelho1,2,
Ricardo Celestino1, Hugo Prazeres1,4, Luis Lima2,5,6,7, Miguel Melo8,9, Adriana Gaspar da Rocha1,3, Ana Preto1,10,
Patrı´cia Castro1, Ligia Castro3,11, Fernando Pardal12, Jose´ Manuel Lopes1,3,11, Lu´cio Lara Santos5,
Rui Manuel Reis13,14, Jose´ Cameselle-Teijeiro15, Manuel Sobrinho-Simo˜es1,3,11, Jorge Lima1,3,
Valdemar Ma´ximo1,3 & Paula Soares1,3
Reactivation of telomerase has been implicated in human tumorigenesis, but the underlying
mechanisms remain poorly understood. Here we report the presence of recurrent somatic
mutations in the TERT promoter in cancers of the central nervous system (43%), bladder
(59%), thyroid (follicular cell-derived, 10%) and skin (melanoma, 29%). In thyroid cancers,
the presence of TERT promoter mutations (when occurring together with BRAF mutations) is
signiﬁcantly associated with higher TERT mRNA expression, and in glioblastoma we ﬁnd a
trend for increased telomerase expression in cases harbouring TERT promoter mutations.
Both in thyroid cancers and glioblastoma, TERT promoter mutations are signiﬁcantly
associated with older age of the patients. Our results show that TERTpromoter mutations are
relatively frequent in speciﬁc types of human cancers, where they lead to enhanced
expression of telomerase.
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R
eactivation or re-expression of telomerase is referred to be a
widespread feature in human cancers, although the genetic
basis remains poorly understood in many cancer types.
Somatic mutations in the coding region of TERT (human
telomerase reverse transcriptase) are infrequent in human
tumours, but germline and somatic mutations in TERT promoter
were recently found in a high percentage of human melanomas
and human cancer cell lines1,2. Such mutations occurred in two
hotspot positions, located  124 and  146 bp upstream from
the ATG start site ( 124 G4A and  146 G4A, C4T on
opposite strand) and conferred enhanced TERT promoter
activity1,2, by putatively generating a consensus binding site
(GGAA) for ETS transcription factors within the TERT promoter
region1,2.
Our aim was to investigate whether the aforementioned TERT
promoter mutations were present in cancer types other than
melanoma, having for that matter screened 741 primary tumours
from the thyroid, kidney, bladder, gastrointestinal stromal
tumour (GIST), adrenal medulla (phaeochromocytomas) and
central nervous system (CNS). Besides skin melanoma, we have
also included ocular melanoma (not studied in the previous
reports), benign lesions of the thyroid and skin and 58 human
cancer-derived cell lines. Our results highlight TERT promoter
mutations as frequent events in speciﬁc types of human cancers.
Results
TERT mutations in tumours and cell lines. Overall, TERT
promoter mutations were found in 142 (19%) human tumour
samples (Table 1; Fig. 1a) and 14 (24%) human cell lines (Fig. 1b;
Supplementary Tables S1 and S2). The  124-bp mutation was
the most frequent, being present in 99 cases, whereas the  146-
bp mutation was present in 43 cases. The  124 G4A and  146
G4A mutations were found in a mutually exclusive fashion. Two
tandem GG4AA mutations at positions  124/ 125 and
 138/ 139 bp were observed in one cell line each
(Supplementary Fig. S1 and Supplementary Table S1). TERT
promoter mutations were not detected in normal thyroid tissue
nor in benign lesions (nevi, thyroiditis, goitres and adenomas).
No mutations were detected in 26 kidney cancers, 17 phaeo-
chromocytomas and 36 GISTs.
TERT mutations in melanoma. We have analysed both skin and
ocular melanomas, a type of melanoma that was not previously
studied1,2. TERT mutations were present in 16 out of 56 (29%)
skin melanomas, but absent in the 25 ocular melanomas
(Table 1). All the four skin melanoma-derived cell lines but
none of the six ocular melanoma-derived cell lines harboured
TERT mutations (Fig. 1b and Supplementary Table S1). Ten out
of 16 (63%) skin melanomas with TERT mutation also harboured
the BRAFV600E mutation, whereas the BRAF mutation was
present in 9 out of 38 (24%) melanomas without TERT mutation
(P¼ 0.01, Fisher’s exact test, two-sided) (Supplementary Fig. S2
and Supplementary Table S3).
TERT mutations in CNS tumours. In CNS tumours, TERT
promoter mutations were found in 43% (51/118) of all cases
with an equal prevalence of both mutations (Table 1 and
Supplementary Table S4). The frequency of TERT mutations was
different according to the tumour histology and grade (Fig. 1c):
although pilocytic astrocytomas (World Health Organization
(WHO) grade 1) and diffuse astrocytoma (WHO grade 2) showed
a lower frequency of mutations (8% and 15%, respectively),
the most aggressive form, glioblastoma multiforme (GBM;
WHO grade 4), present the highest frequency of TERT mutations
(62%). Oligodendrogliomas (WHO grade 2) and anaplastic
oligodendrogliomas (WHO grade 3) also harboured a high fre-
quency of TERT mutations (45% and 54%, respectively).
The presence of TERT mutations was signiﬁcantly associated
with a higher mean age at diagnosis (Supplementary Table S5) in
CNS patients as a whole (Po0.0001; Mann–Whitney test, two-
tailed) and also in GBM patients only (P¼ 0.0247; Mann–
Whitney test, two-tailed); in oligodendroglioma patients, we
found the same trend, although not statistically signiﬁcant
(P¼ 0.0709; Mann–Whitney test, two-tailed). In addition, we
observed that, in a subset of 14 GBM (8 TERT wild-type tumours
and 6 TERT-mutated tumours), the tumours with TERT
mutations showed a trend to increased immunohistochemistry
(IHC) expression of telomerase, although this difference was
not statistically signiﬁcant (P¼ 0.4250; Mann–Whitney test,
two-tailed) (Fig. 2).
TERT mutations in thyroid cancer. We analysed a large series of
follicular cell-derived thyroid samples including normal thyroid
(n¼ 27), benign (n¼ 81) and malignant lesions (n¼ 263)
(Table 1 and Supplementary Table S6). TERT mutations were
only detected in malignant tumours (10%) (Fig. 1d), namely in
Table 1 | Prevalence of TERT promoter recurrent mutations
in human cancers.
Organ/tissue Number TERTmutation, N (%)
Melanocytes
Nevi 9 0
Skin melanoma 56 16 (29%)
Ocular melanoma 25 0
CNS
Pilocytic astrocytoma 13 1 (8%)
Diffuse astrocytoma 20 3 (15%)
Oligodendroglioma 22 10 (45%)
Anaplastic oligodendroglioma 24 13 (54%)
Glioblastoma 39 24 (62%)
Thyroid
Benign 81 0
PTC 169 13 (8%)
FTC 64 9 (14%)
PDTC 14 3 (21%)
ATC 16 2 (13%)
MTC 28 0
Bladder
Low grade 21 14 (67%)
High grade 61 34 (56%)
Kidney
CCRCC 12 0
CromRCC 4 0
PRCC 10 0
Adrenal
Phaeochromocytoma 17 0
GI
GIST 36 0
Total 741 142 (19%)
ATC, anaplastic thyroid carcinoma; CCRCC, clear cell renal cell carcinoma; CNS, central nervous
system; CromRCC, chromophobe renal cell carcinoma; FTC, follicular thyroid carcinoma;
GI, gastrointestinal; GIST, gastrointestinal stromal tumour; MTC, medullary thyroid carcinoma;
PDTC, poorly differentiated thyroid carcinoma; PRCC, papillary renal cell carcinoma; PTC,
papillary thyroid carcinoma.
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11% of papillary thyroid carcinomas (PTCs), 14% of follicular
thyroid carcinomas, 21% of poorly differentiated thyroid carci-
nomas and 13% of the anaplastic thyroid carcinomas. Within the
group of PTC, TERT mutations were detected to be associated to
the so-called conventional PTC (cPTC) (11%).The majority of
TERT-mutated thyroid cancers harboured the  124 G4A
mutation (22 out of 27 cases) (Fig. 1d and Supplementary
Table S7). In thyroid cancer patients, TERT mutations were sig-
niﬁcantly associated with guarded prognosis features such as
larger tumours (P¼ 0.008; Mann–Whitney test, two-tailed),
older patients (Po0.0001; Mann–Whitney test, two-tailed)
and male gender (P¼ 0.0312; Fisher’s exact test, two-sided)
(Supplementary Table S5). After histotype stratiﬁcation, such
correlations were only kept in the group of cPTC where we
also found signiﬁcant associations with lymph node metastasis
(P¼ 0.0318; Fisher’s exact test, two-sided) and BRAFV600E
mutation (P¼ 0.001; Fisher’s exact test, two-sided)
(Supplementary Fig. S2 and Supplementary Table S8). Accord-
ingly, we veriﬁed by quantitative RT-PCR (qPCR) that TERT
mRNA is expressed at variable amounts in thyroid tumours, and
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Figure 1 | Frequency and schematic illustration of TERT promoter mutations in human cancers. Graphics depict the overall frequency of TERTmutations
in the four tumour types where TERTmutations were detected (a) and a bar plot showing the number of cell lines of different origin that harbour
TERTmutations (b). The frequency and type of TERTmutations in different histological subtypes of CNS (c), thyroid (d) and bladder (e) tumours is also
shown. A, diffuse astrocytoma; AO, anaplastic oligodendroglioma; ATC, anaplastic thyroid carcinoma; GB-glioblastoma; FTC, follicular thyroid carcinoma;
O, oligodendroglioma; PA, pilocytic astrocytoma; PDTC, poorly differentiated thyroid carcinoma.
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Figure 2 | IHC for TERT in two glioblastomas. (a)A tumour without TERTexpression and without TERTmutation. (b) A tumour with positive staining both
in nucleus and cytoplasm that also harboured a TERTmutation. The graph (c) displays quantiﬁcation of TERT nuclear expression level (IHC) in
glioblastomas with and without TERTmutation. We have measured the extent (o25%, 25–50%, 50–75% and 475%) and the intensity (absent, faint,
moderate or strong) of TERT nuclear staining in 14 glioblastomas (eight TERT wild type and six TERTmutant). The scoring was performed by two
independent observers and is the product of extent and intensity of the staining (Methods). Scale bar, 200mm. There is a trend to higher TERTexpression
in TERT-mutated gliomas, although the difference was not statistically signiﬁcant (P¼0.4250; Mann–Whitney test, two-tailed). Bars represent s.e.m.
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the ones with coexistent TERT and BRAF mutations showed the
highest levels of TERT mRNA expression (P¼ 0.0001, unpaired
t-test; Fig. 3).
TERT mutations in bladder cancer. In bladder cancer, TERT
mutations were frequently detected (48/82; 59%) both in low-
grade tumours (14/21; 67%) and high-grade tumours (34/61;
56%) (Table 1 and Fig. 1e; Supplementary Table S9). The  124
G4A mutation was present in 30 cases, whereas the  146 G4A
was found in 18 cases. No association was found between the
presence of the mutation and the age of the patients.
No mutations were detected in 26 kidney cancers, 17
phaeochromocytoma and 36 GISTs (Supplementary Tables S10,
S11 and S12, respectively).
Discussion
Recent ﬁndings have described that TERT promoter mutations
arise as a novel mechanism of telomerase reactivation/expression
in human cancers1,2. In this work, we report for the ﬁrst time the
presence of these mutations in different histotypes of thyroid
cancer, and our results validate the ﬁndings reported by others in
melanoma, bladder and gliomas1–3. Furthermore, we present for
the ﬁrst time evidence showing that TERT promoter mutations
are signiﬁcantly associated with increased TERT mRNA
expression in thyroid cancers. We also found a trend for
increased telomerase expression in cases of GBM harbouring
TERT promoter mutations. In thyroid cancers, TERT mRNA was
particularly high in cases harbouring both TERT and BRAF
mutations.
The location of these mutations in the TERT promoter, rather
than the coding region of the gene, creating additional binding
sites for transcription factors, represents also a novel mechanism
of genetic activation in cancer.
The frequency of TERT mutations we detected in skin
melanomas is similar to that reported by Horn et al.1 in
primary melanomas (33%), but lower than the frequency found
by the same authors in metastatic melanomas (85%) and by
Huang et al.2 in a series of 70 melanomas and short-term
cultures1,2. In our series, we have analysed few metastatic
melanomas that did not show a signiﬁcantly higher percentage
of TERT mutations. As our series is too small to allow a
conclusion, it remains to be veriﬁed if there is an increased
frequency of TERT mutations in metastatic melanomas, as
suggested by previous reports1,2.
We have conﬁrmed, in skin melanomas, the signiﬁcant
association between TERT and BRAF mutations, as previously
advanced by Horn et al.1, which we now also demonstrate in
thyroid cancers. Interestingly, in benign nevi, which frequently
harbour BRAF mutations, we did not detect TERT mutations.
This ﬁnding, together with the high frequency of TERT mutations
in metastatic melanomas1, suggests that, although BRAF
mutations are thought to be an early event in melanoma
genesis, TERT mutations may occur at a later stage.
No TERT promoter mutations were found in ocular melano-
mas, which, at variance with skin melanomas, harbour GNAQ
mutations instead of BRAF mutations4,5. Our results further
support the assumption that ocular melanomas result from
different etiopathogenic mechanism than skin melanomas5,6.
Our data on CNS tumours indicate that TERT promoter
mutations are frequent events in gliomas, particularly in GBM
where the highest mutation frequency was found. It has been
shown that TERT mutations conferred enhanced TERT promoter
activity in vitro1,2; our ﬁndings ﬁt with this assumption because
we observed that GBM with TERT promoter mutations appear to
display increased telomerase expression, despite the limited
sensitivity of IHC and the low number of cases analysed. Our
results are also in concordance with those of Lotsch et al.7 who
reported that 60% of GBMs were positive for TERT mRNA and
telomerase activity7. It will be interesting to assess whether the
GBM positive for telomerase activity described by Lotsch et al.7
also harbour TERT promoter mutations. Our ﬁndings also
indicate that TERT mutations are associated with older patients,
in accordance with a recent report3. The high frequency of TERT
mutations in CNS tumours, particularly in intermediate and
high-grade tumours, opens a window for new approaches in the
therapy of CNS tumours.
In thyroid cancer, TERT mutations were only found in
follicular cell-derived cancers (PTC, follicular thyroid carcinoma,
poorly differentiated thyroid carcinoma and anaplastic thyroid
carcinoma). No mutations were detected in medullary thyroid
carcinomas, as described by Killela et al.3, nor in normal thyroid
and benign lesions, such as goitre, adenomas or thyroiditis; this
ﬁnding ﬁts with previous studies that reported telomerase
expression in malignant lesions and not in normal tissue or
hyperplastic lesions8,9. TERT mutations were associated with
clinicopathological features (older age, increased tumour size and
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Figure 3 | Quantiﬁcation of TERT mRNA expression level in thyroid tumours. We have performed qPCR in normal thyroid tissue (N), a pool of
mRNA of nine normal thyroids (pool N) and thyroid tumours with different genetic backgrounds: without known genetic alterations (wt), with BRAF
mutation (B), with RET rearrangement (RET), with RAS mutation (R), with TERTmutation (T), with TERT and BRAF mutations (BT) or with RAS and TERT
mutations (RT). (a) Each bar represents TERTmRNA expression in an individual tumour measured in triplicate. TERTmRNA levels were normalized
against TBP mRNA levels. (b) Quantiﬁcation of TERTmRNA mean expression level in thyroid tumours with and without TERTmutation. Error bars represent
s.e.m. The difference is statistically signiﬁcant (Po0.0001, unpaired t-test).
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male gender), but, after histotype stratiﬁcation, these associations
were only maintained in cPTC. Studies in larger series will be
necessary to clarify these associations. In cPTC, TERT mutations
were associated with BRAF mutation, highlighting the coexistence
of activation of BRAF and TERT, previously reported in
melanoma1 (Supplementary Fig. S2). Our results reinforce the
hypothesis of a link between BRAF activation and telomerase
expression, which can be mediated by transcription factors
binding to the newly created consensus binding sites, as
previously advanced by Horn et al.1. Both in thyroid carcinoma
and melanoma, it seems that a ‘background’ status of activated
BRAF enhances the effects of TERT promoter mutation. Our
results in TERT mRNA expression strengthen this assumption,
showing, for the ﬁrst time, an increased TERT expression in
tumours harbouring BRAF and TERT mutation (Fig. 3). Further
observational and mechanistic studies are needed to clarify these
points.
TERT alterations seem to constitute an early and frequent
event in bladder cancer. These ﬁndings ﬁt with the high
prevalence of telomerase activity previously described in bladder
tumours10. The recurrent hotspot mutations in TERT were
advanced to be, in melanomas, induced by ultraviolet radiation2.
Bladder is a target for several chemical carcinogens; it remains to
be found whether TERT mutations can also result from the action
of such agents. The identiﬁcation of TERT mutations in urine
may provide a biomarker for early diagnosis and monitoring of
bladder cancer.
No TERT mutations were detected in kidney cancers, nor in 17
phaeochromocytoma and 36 GISTs. The underlying reasons for
the tissue speciﬁcity of TERT mutations remain to be clariﬁed.
We can hypothesize that TERT mutations can be present in two
settings. As described by Killela et al.3, TERT mutations can be
relevant in tissues with relative low rates of self-renewal, which
ﬁts with our ﬁndings in follicular cell-derived thyroid cancer and
gliomas where they are associated with the older age of the
patients. On the other hand, these mutations can also result from
environmental factors such as ultraviolet radiation and chemical
carcinogens as suggested by their high frequency in melanoma,
bladder and tongue1–3. In summary, our data identify TERT
mutations as common events in human cancers and support the
assumption that TERT promoter mutations may be one of the
mechanisms that underlies telomerase reactivation in several
types of human tumours.
Methods
Human cancer samples. All the procedures described in this study were in
accordance with national and institutional ethical standards and previously
approved by Local Ethical Review Committees. According to Portuguese law,
informed consent is not required for retrospective studies.
Formalin-ﬁxed, parafﬁn-embedded tissues from nine cases of sporadic nevi, 56
cases of sporadic skin melanomas and 25 cases of ocular melanoma were retrieved
from the ﬁles of the Hospital S. Joa˜o (HSJ)/Medical Faculty of Porto (FMUP),
Porto, Portugal, the Department of Pathology of HSJ and the Department of
Pathology of Hospital S. Marcos (HSM), Braga, Portugal. Clinicopathological and
follow-up data were retrieved from the ﬁles of the Department of Pathology,
Department of Dermatology and Oncology Registry of HSJ and Department of
Pathology of HSM, and from RORENO (Oncology Registry of North Region). All
skin melanoma cases were re-evaluated and staged according to the seventh edition
of the American Joint Committee on Cancer11. The overall female:male ratio was
1.2:1. The mean age of the patients was 58 years for females (s.d.±17.6), with a
range from 9 to 94 years, and 62 years for males (s.d.±13.1), with a range from 33
to 79 years.
Follow-up data were available for 53 patients, including the diagnosis of
metastases, through the evaluation of the patients or direct interview with their
relatives and by review of in-hospital patient ﬁles/RORENO. The mean follow-up
time of patients was 41 months (range 1–170). During follow-up, 5 (9%) patients
developed (lymph node, liver or brain) metastases and 8 (15%) patients died due to
malignant melanoma. The remaining patients were alive and without evidence of
melanoma recurrence at the last follow-up. Additional information regarding the
melanoma subtype, age, gender, thickness and molecular analysis of TERT, BRAF
and NRAS is compiled in Supplementary Table S3.
Formalin-ﬁxed, parafﬁn-embedded tissues from 372 tumours and tumour-like
lesions of the thyroid and 27 normal thyroids were collected from the ﬁles of
IPATIMUP, HSJ/FMUP and the Portuguese Institute of Oncology, Coimbra,
Portugal. The histology of all tumour samples was revised, and the ﬁnal
classiﬁcation was made according to the WHO criteria12. In Supplementary Tables
S6 and S7, we have summarized the information regarding histological
classiﬁcation of the lesions, gender, mean age of the patients, molecular data and
the size of the tumours.
Representative formalin-ﬁxed parafﬁn-embedded samples from 118 gliomas
were retrieved from pathology archives of the Department of Pathology of
HSJ/FMUP and the Department of Pathology of HSM, Braga, Portugal. The
tumours were reviewed and classiﬁed according to the WHO classiﬁcation of CNS
tumours (2007) (ref. 13,14). This cohort includes lesions that were classiﬁed as
pilocytic astrocytoma (n¼ 13), astrocytoma grade 2 (n¼ 20), oligodendroglioma
(n¼ 22), anaplastic oligodendroglioma (n¼ 24) and glioblastoma (n¼ 39). Further
information regarding the CNS cases is available in Supplementary Table S4.
Formalin-ﬁxed, parafﬁn-embedded tissues were collected from 82 patients with
non-muscle invasive bladder cancer who underwent transurethral resection of the
bladder malignant tumours in the Portuguese Institute of Oncology, Porto.
Haematoxylin–eosin-stained sections were reviewed according to the standard
histopathological examination by two independent pathologists. Staging and
grading were conducted according to the American Joint Committee on Cancer11,
and the 2004 WHO classiﬁcation system15. Supplementary Table S9 summarizes
the clinicopathological parameters.
Formalin-ﬁxed, parafﬁn-embedded tissues from 26 kidney cancers were
collected from the HSJ/FMUP. Cases were classiﬁed as clear cell renal cell
carcinoma (n¼ 12), chromophobe renal cell carcinoma (n¼ 4) and papillary renal
cell carcinoma (n¼ 10). Information addressing the diagnosis, age, gender, nuclear
grade and staging is obtainable in Supplementary Table S10.
Formalin-ﬁxed, parafﬁn-embedded tissues from 17 pheochromocytomas were
collected from the HSJ/FMUP and IPATIMUP, Porto, Portugal. Supplementary
Table S11 summarizes the clinicopathological parameters.
Formalin-ﬁxed, parafﬁn-embedded tissues from 36 GIST were collected from
the HSJ/FMUP and IPATIMUP, Porto, Portugal. Tumours were classiﬁed
according to the WHO pathological classiﬁcation16, and the parameters analysed in
each case included: age, gender and tumour size. These data and the molecular
characterization of these tumours can be observed in Supplementary Table S12.
Cell lines. DNA from 58 cell lines deposited in IPATIMUP cell line bank was
retrieved. All the cell lines were authenticated using DNA proﬁle analysis, obtained
with the PowerPlex 16 system (Promega, Madison, USA), according to the DNA
proﬁles available in American Type Culture Collection and Health Science
Research Resource Bank.
DNA extraction. DNA from formalin-ﬁxed, parafﬁn-embedded tissues was
retrieved from 10-mm cuts after careful microdissection. DNA extraction was
performed using the Ultraprep Tissue DNA Kit (AHN Biotechnologie, Nordhau-
sen, Germany) following the manufacturer’s instructions.
RNA extraction. Total RNA was extracted from frozen thyroid tumours (n¼ 24)
and normal tissue specimens (n¼ 3) using a Trizol commercial kit (Life Tech-
nologies, GIBCO BRL, Carlsbad, CA) according to the manufacturer’s protocol.
RNA was quantiﬁed spectrophotometrically, and its quality was checked by ana-
lysis of 260/280Zm and 260/230Zm ratios.
PCR and Sanger sequencing. Coding regions of BRAF, GNAQ HRAS, NRAS,
cKIT and PDGFR were screened for mutations in DNA extracted from parafﬁn
blocks using PCR and Sanger sequencing. The genetic characterization of part of
the tumours had already been previously reported. For information on primers and
PCR conditions, see refs 5,17,18. To screen for TERT promoter mutations, we
analysed the hotspots previously identiﬁed by PCR followed by Sanger sequencing.
TERT promoter mutation analysis was performed with the pair of primers
FwTERT: 50-CAGCGCTGCCTGAAACTC-30 and RwTERT: 50-GTCCTGCCCC
TTCACCTT-30 . Ampliﬁcation of genomic DNA (25–100 ng) was performed by
PCR using the Qiagen Multiplex PCR kit (Qiagen, Hilden, Germany) according to
the manufacturer’s instructions. Sequencing reaction was performed with the ABI
Prism BigDye Terminator Kit (Perkin-Elmer, Foster City, CA), and the fragments
were run in an ABI prism 3100 Genetic Analyser (Perkin-Elmer). The sequencing
reaction was performed in a forward direction, and an independent PCR
ampliﬁcation/sequencing, both in a forward and reverse direction, was performed
in positive samples or samples that were inconclusive.
Quantitative RT-PCR. qPCR for human TERT was performed in 28 thyroid
samples, 24 tumours and 3 normal tissue specimens. We also included a normal
reference that was produced by pooling RNAs from nine samples of normal
thyroid tissue19.
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For cDNA preparation, 1 mg of total RNA was reverse transcribed using the
RevertAid ﬁrst strand cDNA synthesis kit (Fermentas, Burlington, ON, Canada).
Reverse transcription products were ampliﬁed for the TERT by qPCR (IDT; no.
HS.PT.56a.40988589) using TaqMan PCR Master Mix (Applied Biosystems, Foster
City, CA, USA) with TBP gene (TATA-binding protein) as endogenous control
(Applied Biosystems; no. 4326322E-0705006). The ABI PRISM 7500 Fast Sequence
Detection System (Applied Biosystems) was used to detect the ampliﬁcation level
and was programmed to an initial step of 2min at 50 C, 10min at 95 C, followed
by 45 cycles of 95 C for 15 s and 60 C for 1min. TBP and TERT ampliﬁcations
were done in triplicate using 1 ml of cDNA (B50 ng) for each sample. The relative
quantiﬁcation of target genes was determined using the DDCT method, which was
previously validated by Livak’s Linear Regression Method (slope¼ 0.0696)
(Sequence Detector User Bulletin 2; Applied Biosystems).
Immunohistochemistry. IHC for telomerase was performed in representative
tumour tissue sections of 14 glioblastomas. Brieﬂy, deparafﬁnized and rehydrated
sections were subjected to microwave treatment in 10mM sodium citrate buffer,
pH 6.0, for antigen retrieval. The sections were incubated overnight at 4 C in a
humidiﬁed chamber with the primary antibody telomerase (polyclonal, rabbit,
1:500) from Rockland Immunochemicals Inc., Gilbertsville, PA. The detection was
performed with a labelled streptavidin–biotin immunoperoxidase detection system
(Thermo Scientiﬁc/Lab Vision, Fremont, USA), and the immunohistochemical
staining was developed with 3,30-diaminobenzidine substrate. Omission of the
primary antibody incubation was used as negative control. Previously tested liver
cancer case was used as positive control. IHC evaluation was performed inde-
pendently by two observers (V.M. and J.L.). An IHC score was established, which
corresponded to the product of the intensity of expression (absent¼ 0, faint¼ 1,
moderate¼ 2 and strong¼ 3) with the tumour extent of protein expression
(0–25%¼ 0, 26–50%¼ 1, 51–75%¼ 2 and 475%¼ 3) (ref. 6).
Statistical analysis. Statistical analysis was conducted with StatView for Win-
dows, version 5.0 (SAS Institute, Cary, NC). The results are expressed as a per-
centage or mean±s.d. Statistical analysis was performed both on the whole series
and considering the different groups of lesions. For the analysis of the relationship
between patients’ age, tumour size and TERT status of the tumours, we used the
unpaired t-test, Mann–Whitney test and analysis of variance. Fisher’s exact test was
used in the statistical analysis of the other parameters. Graphs and ﬁgures were
done in GraphPad v6.0. Results were considered statistically signiﬁcant if Po0.05.
References
1. Horn, S. et al. TERT promoter mutations in familial and sporadic melanoma.
Science 339, 959–961 (2013).
2. Huang, F. W. et al. Highly recurrent TERT promoter mutations in human
melanoma. Science 339, 957–959 (2013).
3. Killela, P. J. et al. TERT promoter mutations occur frequently in gliomas and a
subset of tumors derived from cells with low rates of self-renewal. Proc. Natl
Acad. Sci. USA 110, 6021–6026 (2013).
4. Van Raamsdonk, C. D. et al. Frequent somatic mutations of GNAQ in uveal
melanoma and blue naevi. Nature 457, 599–602 (2009).
5. Populo, H., Vinagre, J., Lopes, J. M. & Soares, P. Analysis of GNAQ mutations,
proliferation and MAPK pathway activation in uveal melanomas. Br. J.
Ophthalmol. 95, 715–719 (2011).
6. Populo, H., Soares, P., Rocha, A. S., Silva, P. & Lopes, J. M. Evaluation of the
mTOR pathway in ocular (uvea and conjunctiva) melanoma. Melanoma Res.
20, 107–117 (2010).
7. Lotsch, D. et al. Prognostic signiﬁcance of telomerase-associated parameters in
glioblastoma: effect of patient age. Neuro. Oncol. 15, 423–432 (2013).
8. Soares, P. et al. Genetic alterations in poorly differentiated and undifferentiated
thyroid carcinomas. Curr. Genomics 12, 609–617 (2011).
9. Capezzone, M. et al. Telomere length in neoplastic and nonneoplastic tissues of
patients with familial and sporadic papillary thyroid cancer. J. Clin. Endocrinol.
Metab. 96, E1852–E1856 (2011).
10. Sanchini, M. A. et al. Relevance of urine telomerase in the diagnosis of bladder
cancer. JAMA 294, 2052–2056 (2005).
11. Edge, S. B. et al. AJCC Cancer Staging Manual (Springer, 2010).
12. DeLellis, R. A., L.R., Heitz, P. U. & Eng, C. (eds) World Health Organization
Classiﬁcation of Tumours. Pathology and Genetics of Tumours of Endocrine
Glands (IARC Press, 2004).
13. Kleihues, P. & Cavenee, W. K. Pathology and Genetics of Tumours of the
Nervous System (IARC Press, 2000).
14. Louis, D. N. et al. The 2007 WHO classiﬁcation of tumours of the central
nervous system. Acta Neuropathol. 114, 97–109 2007.
15. Sauter, G. et al. in WHO Classiﬁcation of Tumors. Pathology and Genetics of
Tumors of the Urinary System and Male Genital Organs. (eds Eble, J.N., Sauter,
G., Epstein, J.I. & Sesterhenn, I.A.) (IARC Press, 2004).
16. Fletcher, C. D. et al. Diagnosis of gastrointestinal stromal tumors: a consensus
approach. Hum. Pathol. 33, 459–465 (2002).
17. Soares, P. et al. BRAF mutations and RET/PTC rearrangements are alternative
events in the etiopathogenesis of PTC. Oncogene 22, 4578–4580 (2003).
18. Celestino, R. et al. Molecular alterations and expression of succinate
dehydrogenase complex in wild-type KIT/PDGFRA/BRAF gastrointestinal
stromal tumors. Eur. J. Hum. Genet. 21, 503–510 (2013).
19. Prazeres, H. et al. Chromosomal, epigenetic and microRNA-mediated
inactivation of LRP1B, a modulator of the extracellular environment of thyroid
cancer cells. Oncogene 30, 1302–1317 (2011).
Acknowledgements
We thank to Mrs Mafalda Rocha for the excellent technical support in the sequencing
work. This work was partially supported by the Portuguese Science and Technology
Foundation (FCT) through BPD (SFRH/BPD/85249/2012 to H.P.), PhD (SFRH/BD/
81940/2011 to J.V. and SFRH/BD/79135/2011 to A.A.) and BI grants, and the grant
through the Program Cieˆncia 2008 (J.L.) and the project (PIC/IC/83037/2007). Further
funding was obtained from the project ‘Microenvironment, metabolism and cancer’
partially supported by Programa Operacional Regional do Norte (ON.2—O Novo Norte),
under the Quadro de Refereˆncia Estrate´gico Nacional (QREN), and through the Fundo
Europeu de Desenvolvimento Regional (FEDER). IPATIMUP is an associate laboratory of
the Portuguese Ministry of Science, Technology and Higher Education and is partially
supported by the FCT.
Author contributions
J.V., A.A. and H.P. contributed equally to the work. P.S. and V.M. jointly supervised the
research. P.S. conceived the study. P.S., V.M. and J.L. designed the experiments. J.V.,
A.A., H.P., J.Ly., V.P., R.C., R.Ce., R.B., P.C., H.P., M.M. and A.R. performed the DNA
extraction and mutation analysis experiments. R.B. performed the qPCR experiments.
H.P. performed the IHC studies. M.S.S., L.C., J.C.-T. and J.M.L. performed the tumour
classiﬁcation. A.P., L.L., F.P., L.L.S. and R.R. provided tumour samples, reagents and
collected the clinicopathological data. P.S., V.M., J.L., J.V., H.P., R.B. and M.S.S. wrote the
paper with the contribution of all the other authors.
Additional information
Supplementary Information accompanies this paper at http://www.nature.com/
naturecommunications
Competing ﬁnancial interests: The authors declare no competing ﬁnancial interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
How to cite this article: Vinagre, J. et al. Frequency of TERT promoter mutations in
human cancers. Nat. Commun. 4:2185 doi: 10.1038/ncomms3185 (2013).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms3185
6 NATURE COMMUNICATIONS | 4:2185 | DOI: 10.1038/ncomms3185 | www.nature.com/naturecommunications
& 2013 Macmillan Publishers Limited. All rights reserved.
